微小RNA调控肝细胞癌索拉非尼耐药的分子机制

Molecular mechanism of microRNAs regulating sorafenib resistance in hepatocellular carcinoma

肝细胞癌是全球最致命的恶性肿瘤之一,侵袭性强,治愈率低,转移率高,预后极差。索拉非尼是治疗晚期肝细胞癌最主要且有效的一线治疗药物,但原发和获得性耐药,严重限制其临床疗效。微小RNA是一种小非编码RNA,在肝细胞癌的发生、发展,以及索拉非尼耐药进展中扮演着关键的调控角色。该文总结了微小RNA在肝细胞癌索拉非尼耐药的起始和发展中的作用,旨在进一步了解索拉非尼抗肝癌的机制,并为肝细胞癌的临床靶向治疗,及预后改善提供有价值的理论依据。

Hepatocellular carcinoma(HCC)is one of the most deadly malignancies in the world,with strong invasiveness,low cure rate,high metastasis rate and poor prognosis.Sorafenib is the most important and effective first-line drug for the treatment of advanced hepatocellular carcinoma,but its clinical efficacy is severely limited by primary and acquired drug resistance.Micrornas(micrornas)are small non-coding Rnas that play a key regulatory role in the occurrence and development of hepatocellular carcinoma and the progression of sorafenib resistance.This paper summarizes the role of micrornas in the initiation and development of sorafenib resistance in hepatocellular carcinoma,in order to further understand the mechanism of sorafenib anti-hepatocellular carcinoma,and to provide valuable theoretical basis for clinical targeted therapy and prognosis improvement in hepatocellular carcinoma.